Jin Hyoung Kang

4.9k total citations
116 papers, 3.1k citations indexed

About

Jin Hyoung Kang is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Jin Hyoung Kang has authored 116 papers receiving a total of 3.1k indexed citations (citations by other indexed papers that have themselves been cited), including 74 papers in Pulmonary and Respiratory Medicine, 63 papers in Oncology and 26 papers in Surgery. Recurrent topics in Jin Hyoung Kang's work include Lung Cancer Treatments and Mutations (62 papers), Lung Cancer Research Studies (26 papers) and Colorectal Cancer Treatments and Studies (25 papers). Jin Hyoung Kang is often cited by papers focused on Lung Cancer Treatments and Mutations (62 papers), Lung Cancer Research Studies (26 papers) and Colorectal Cancer Treatments and Studies (25 papers). Jin Hyoung Kang collaborates with scholars based in South Korea, United States and Taiwan. Jin Hyoung Kang's co-authors include Jeong‐Sun Seo, Young Tae Kim, Thomas Bleazard, Won‐Chul Lee, Young Seok Ju, Jong‐Il Kim, Jong-Yeon Shin, Keunchil Park, Myung‐Ju Ahn and Sang-We Kim and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Clinical Cancer Research.

In The Last Decade

Jin Hyoung Kang

110 papers receiving 3.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jin Hyoung Kang South Korea	28	1.9k	1.7k	1.0k	679	472	116	3.1k
Vincenzo Adamo Italy	27	2.2k 1.2×	2.4k 1.4×	1.0k 1.0×	699 1.0×	367 0.8×	118	3.8k
Joo Hang Kim South Korea	27	1.9k 1.0×	1.9k 1.1×	789 0.8×	426 0.6×	326 0.7×	91	3.0k
Feng‐Hua Wang China	31	861 0.5×	1.5k 0.9×	872 0.9×	822 1.2×	637 1.3×	126	2.9k
Shaodong Hong China	28	1.8k 1.0×	2.9k 1.7×	619 0.6×	605 0.9×	463 1.0×	128	3.9k
Mara Ghilardi Italy	29	1.0k 0.6×	1.8k 1.0×	402 0.4×	529 0.8×	627 1.3×	70	2.6k
José Á. García-Sáenz Spain	29	1.0k 0.6×	2.1k 1.2×	631 0.6×	1.0k 1.5×	233 0.5×	162	3.0k
Takeshi Hanagiri Japan	35	1.8k 1.0×	1.8k 1.1×	1.2k 1.2×	448 0.7×	552 1.2×	207	3.9k
Frank Dunphy United States	25	2.1k 1.1×	2.4k 1.4×	735 0.7×	476 0.7×	334 0.7×	65	3.6k
Elie Rassy Lebanon	29	805 0.4×	1.7k 1.0×	727 0.7×	444 0.7×	302 0.6×	163	2.7k
Kathryn A. Gold United States	29	1.8k 1.0×	2.1k 1.3×	922 0.9×	463 0.7×	338 0.7×	99	3.5k

Countries citing papers authored by Jin Hyoung Kang

Since Specialization

Citations

This map shows the geographic impact of Jin Hyoung Kang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jin Hyoung Kang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jin Hyoung Kang more than expected).

Fields of papers citing papers by Jin Hyoung Kang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jin Hyoung Kang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jin Hyoung Kang. The network helps show where Jin Hyoung Kang may publish in the future.

Co-authorship network of co-authors of Jin Hyoung Kang

This figure shows the co-authorship network connecting the top 25 collaborators of Jin Hyoung Kang. A scholar is included among the top collaborators of Jin Hyoung Kang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jin Hyoung Kang. Jin Hyoung Kang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Goss, Geraldine, Gail Darling, Virginie Westeel, et al.. (2024). LBA48 CCTG BR.31: A global, double-blind placebo-controlled, randomized phase III study of adjuvant durvalumab in completely resected non-small cell lung cancer (NSCLC). Annals of Oncology. 35. S1238–S1238. 17 indexed citations

Lee, Keun Seok, Woo Jin Lee, Heejung Chae, et al.. (2023). Co-mutation of ATM and ASXL1 and relationship to durable response of a novel PARP1/2 inhibitor, venadaparib, in patients with pancreatic cancer.. Journal of Clinical Oncology. 41(16_suppl). e15019–e15019.

Ha, Hyerim, et al.. (2022). The value measurement of emerging therapeutics in renal cell carcinoma: ASCO value framework and ESMO-MCBS. BMC Health Services Research. 22(1). 900–900. 3 indexed citations

Kim, Do Yeun, Hyerim Ha, SeungJin Bae, & Jin Hyoung Kang. (2021). Should We Consider Value Frameworks for Cancer Drugs as Oncology's Landscape Evolves?; from an Oncologist Perspective in Korea. Journal of Korean Medical Science. 36(29). e191–e191. 1 indexed citations

Park, Seo‐Young, S.T. Kim, Jin Hyoung Kang, et al.. (2020). A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy. Annals of Oncology. 31(10). 1397–1404. 122 indexed citations

Lee, Miran, et al.. (2020). A Highly Sensitive Next-Generation Sequencing-Based Genotyping Platform for EGFR Mutations in Plasma from Non-Small Cell Lung Cancer Patients. Cancers. 12(12). 3579–3579. 1 indexed citations

Yang, James Chih‐Hsin, Ying Cheng, Haruyasu Murakami, et al.. (2019). A Randomized Phase 2 Study of Gefitinib With or Without Pemetrexed as First-line Treatment in Nonsquamous NSCLC With EGFR Mutation: Final Overall Survival and Biomarker Analysis. Journal of Thoracic Oncology. 15(1). 91–100. 31 indexed citations

Kwon, Jung Hye, Jin Hyoung Kang, Ho Jung An, et al.. (2018). Ramosetron versus palonosetron in combination with aprepitant and dexamethasone for the control of highly emetogenic chemotherapy-induced nausea and vomiting. Annals of Oncology. 29. viii610–viii610. 1 indexed citations

An, Ho Jung, Sook Hee Hong, Young Kyoon Kim, et al.. (2017). MA16.05 For EGFR Mutant Non-Small Cell Lung Cancer, Treatment Sequence Matters?. Journal of Thoracic Oncology. 12(1). S436–S437. 1 indexed citations

10.

Boye, Mark E., Xin Wang, Vichien Srimuninnimit, et al.. (2015). First-Line Pemetrexed Plus Cisplatin Followed by Gefitinib Maintenance Therapy Versus Gefitinib Monotherapy in East Asian Never-Smoker Patients With Locally Advanced or Metastatic Nonsquamous Non–Small-cell Lung Cancer: Quality of Life Results From a Randomized Phase III Trial. Clinical Lung Cancer. 17(2). 150–160. 13 indexed citations

11.

Lee, Dong Soo, Seung Joon Kim, Hong Seok Jang, et al.. (2015). Clinical Correlation Between Tumor Maximal Standardized Uptake Value in Metabolic Imaging and Metastatic Tumor Characteristics in Advanced Non-small Cell Lung Cancer. Medicine. 94(32). e1304–e1304. 9 indexed citations

12.

Kim, Hye Sook, Jae Sook Sung, Nak‐Jung Kwon, et al.. (2013). Predictive Efficacy of Low Burden EGFR Mutation Detected by Next-Generation Sequencing on Response to EGFR Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Carcinoma. PLoS ONE. 8(12). e81975–e81975. 18 indexed citations

13.

Seo, Jeong‐Sun, Young Seok Ju, Won‐Chul Lee, et al.. (2012). The transcriptional landscape and mutational profile of lung adenocarcinoma. Genome Research. 22(11). 2109–2119. 427 indexed citations

14.

Ju, Young Seok, Won‐Chul Lee, Jong-Yeon Shin, et al.. (2011). A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing. Genome Research. 22(3). 436–445. 351 indexed citations

15.

Salto‐Tellez, Manuel, Ming‐Sound Tsao, Jin‐Yuan Shih, et al.. (2011). Clinical and Testing Protocols for the Analysis of Epidermal Growth Factor Receptor Mutations in East Asian Patients with Non-small Cell Lung Cancer: A Combined Clinical-Molecular Pathological Approach. Journal of Thoracic Oncology. 6(10). 1663–1669. 33 indexed citations

16.

Hong, Sook Hee, Yoon Ho Ko, Hye Sung Won, et al.. (2010). Prognostic Significance of Glycolytic Metabolic Change Related to HIF-1α in Oral Squamous Cell Carcinomas. The Korean Journal of Pathology. 44(4). 360–360. 2 indexed citations

17.

Kim, Dong‐Wan, Se‐Hoon Lee, Jong Seok Lee, et al.. (2010). A multicenter phase II study to evaluate the efficacy and safety of gefitinib as first-line treatment for Korean patients with advanced pulmonary adenocarcinoma harboring EGFR mutations. Lung Cancer. 71(1). 65–69. 33 indexed citations

18.

Lee, Myung Ah, et al.. (2007). Genetic Polymorphisms of UGT1A and their Association with Clinical Factors in Healthy Koreans. Genomics & Informatics. 5(4). 161–167. 2 indexed citations

19.

Woo, In Sook, Gi‐Young Kim, Myung Ah Lee, et al.. (2004). Nail Changes During Docetaxel Containing Combination Chemotherapy. The Korean Journal of Internal Medicine. 19(2). 132–133. 2 indexed citations

20.

Park, Chul Soo, Ho‐Joong Youn, Eun Joo Cho, et al.. (2002). Cardioprotective Effect of IGF-1 in Mouse with Adriamycin Induced Cardiomyopathy. Sunhwan'gi. 32(12). 1116–1116. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact